Followers | 183 |
Posts | 25196 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Wednesday, January 12, 2022 2:07:14 PM
January 4, 2022 (Globe Newswire)
Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe
Intended SenlangBio acquisition terminated, eliminating potential 80 million share issuance
Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.
"We believe we have made significant progress in 2021, advancing our scientific and clinical programs focusing on immuno-oncology and cellular medicines," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. "Our goal is to address the unmet needs of patients utilizing innovative technologies that transform cellular therapy and regenerative medicine. We have partnered with world-renowned research centers and universities on cutting edge research, and are accelerating our own innovative research, bio-process development, clinical programs and product commercialization."
Avalon entered into a new collaboration with University of Pittsburgh Medical Center (UPMC) to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients with a rapid bio-manufacturing time (1-2 days instead of weeks). Avalon's lead candidate, AVA-011, combines Avalon's FLASH-CAR(TM) technology with an innovative messenger ribonucleic acid (mRNA)-based technology platform, and is currently at an IND-enabling stage. Avalon is on track to initiate AVA-011 first-in-human clinical trial by mid-2022. This non-viral, next-generation chimeric antigen receptor (CAR)-based cellular therapies approach is expected to streamline and enhance the quality of clinical-grade CAR T-cell manufacturing and the Company believes will result in efficacious, lower cost cellular therapy products, making them accessible to a wider range of cancer patients.
Avalon's research partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria, is rapidly progressing. The co-development of a novel, cell-free, in-silico system with BOKU expands Avalon's ability to design and produce novel cell membrane proteins--including receptors found on the surface of immune cells and cancer cells that function in cell signaling and are important drug targets. This system also provides Avalon with an efficient tool to screen and optimize potential therapeutic targets.
Avalon has co-developed and jointly filed a patent with BOKU on a novel platform of S-layer coated emulsome technology (SLET) for next-generation, targeted drug delivery and cellular immunotherapy applications. The Company believes this novel SLET platform will help accelerate the development of Avalon's mRNA-based Flash-CAR(TM) and other cellular therapy programs. Targeted delivery of mRNA into immune effector cells using SLET can potentially open the door to new generation of cancer immunotherapy and other applications including targeted drug delivery and therapeutics, vaccine development, in vitro diagnostics, and cellular medicines.
"Given our rapid progress this past year, our goal for 2022 is to focus on our core programs to drive innovation and bring about advanced technologies and new medicines to patients. Towards this end, we have decided not to move ahead with the SenlangBio acquisition. Instead, we plan to focus our resources on organic growth and strategic partnership opportunities that we believe will hold the potential to drive much greater value for our shareholders, while avoiding potentially significant dilution that would have occurred with the proposed acquisition. Through strategic investments, we intend to continue to bring high-quality, high-impact programs to enrich Avalon's assets in intellectual properties, R&D and commercialization. Overall, we believe we are extremely well positioned to execute on our growth strategy, and I am highly encouraged by the operational and financial outlook for our business. Last week, we announced that our Chairman converted his loan to common stock at a significant premium to market, showing his further support and confidence in the business. As we head into 2022, we believe we have a number of important upcoming milestones that have the potential to continue to drive significant value for our shareholders," concluded Dr. Jin.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX(TM)), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare's developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com
Recent ALBT News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:31:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 09:01:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/15/2024 08:05:29 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:29:00 PM
- Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 12:18:14 PM
- Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 12:37:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:05:13 PM
- Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:54:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 09:10:10 PM
- Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report • GlobeNewswire Inc. • 05/24/2024 09:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 12:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:17 PM
- Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 04/22/2024 01:00:00 PM
- Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:49:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:30:46 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/20/2023 08:18:23 PM
- Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM